Skip to main content
SpringerLink
Log in

Single- and Multiple-Dose Pharmacokinetics and Tolerability of Gepirone Extended-Release

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective

To determine the single- and multiple-dose pharmacokinetic profile of gepirone extended-release (ER) in healthy individuals.

Methods

The single- and multiple-dose pharmacokinetics of gepirone-ER were investigated in three randomised, placebo-controlled studies of 115 healthy subjects. Dosages ranged from 10 to 75 mg/day for 6 days (study 1), 20 mg/day for 7 days (study 2), and 120 mg/day for 7 days (study 3). Blood samples were obtained to measure plasma levels of gepirone and the l-pyrimidinyl-(2-pipera-zine) [1-PP] metabolite prior to the first dose and other intervals on the first and last treatment days. Pharmacokinetic parameters included peak plasma level (Cmax), time to peak plasma level (tmax), and area under the concentration-time curve (AUC).

Results

In single-dose studies, peak gepirone-ER plasma concentrations were reached in approximately 4 to 5 hours and slowly declined over the next 20 hours. Steady-state plasma gepirone concentrations were reached by day 2 during multiple-dose studies; Cmax, minimum trough plasma concentration (Cmin) and AUC were dose proportional. Greater fluctuations in plasma concentrations were observed with gepirone solution than with gepirone-ER. The AUC for gepirone-ER was approximately 80% of that for gepirone solution. A similar pharmaco-kinetic profile was observed for the 1-PP metabolite. Gepirone-ER was generally well tolerated at all doses in all age groups except for 120 mg/day. The incidence of adverse events, including headache, dizziness and nausea, tended to be higher in gepirone-ER than in placebo recipients.

Conclusions

Gepirone and 1-PP exhibited linear pharmacokinetic profiles. Peak/trough fluctuations in plasma gepirone concentrations were reduced by gepirone-ER, while total exposure to drug (AUC) was maintained. Overall, gepirone-ER was well tolerated. As a result of lower peak plasma levels, gepirone-ER may be expected to reduce the incidence of adverse events compared with gepirone immediate-release and thus has the potential to improve response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Fig. 3
Table III

Similar content being viewed by others

References

  1. Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987; 1: 470–80

    Article  PubMed  CAS  Google Scholar 

  2. Tay LK, Sciacca MA, Sostrin MB, et al. Effect of food on the bioavailability of gepirone in humans. J Clin Pharmacol 1993; 33(7): 631–5

    PubMed  CAS  Google Scholar 

  3. Tay LK, Farmen RH, Pittman KA. Pharmacokinetics (PH) and disposition of gepirone (GEP) and 1-pyrimidinylpiperazine (1-PP) in humans after intravenous (i.v.) and oral (p.o.) administration of 14C-gepirone [abstract]. Pharm Res 1990; 7(9 Suppl. ): S208

    Google Scholar 

  4. Blier P, Curet O, Chaput Y, et al. Tandospirone and its metabolite, l-(2-pyrimidinyl)-piperazine: II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuro-pharmacology 1991; 30(7): 691–701

    CAS  Google Scholar 

  5. Miller LG, Thompson MI, Byrnes JJ, et al. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite l-(2-pyrimidinyl)-piperazine. J Clin Psychopharmacol 1992; 12: 341–5

    PubMed  CAS  Google Scholar 

  6. Rimele TJ, Henry DE, Lee DK, et al. Tissue-dependent alpha adrenoceptor activity of buspirone and related compounds. J Pharmacol Exp Ther 1987; 241(3): 771–8

    PubMed  CAS  Google Scholar 

  7. Giral P, Soubrie P, Puech AJ. Pharmacological evidence for the involvement of l-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems. Eur J Pharmacol 1987; 134(1): 113–6

    Article  PubMed  CAS  Google Scholar 

  8. Gobbi M, Frittoli E, Mennini T. Antagonist properties of l-(2-pyrimidinyl)piperazine at presynaptic alpha 2-adrenoceptors in the rat brain. Eur J Pharmacol 1990; 180(1): 183–6

    Article  PubMed  CAS  Google Scholar 

  9. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982: 409–17

  10. Fitton A, Benfield P. Gepirone in depression and anxiety disorders. CNS Drugs 1994; 1: 388–98

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Drug Metabolism and Kinetics, NV Organon, Molenstraat 110, PO Box 20, 5340 BH, Oss, The Netherlands

    Cees J. Timmer

  2. Clinical Development Department, NV Organon, Oss, The Netherlands

    J. M. A. Sitsen

Authors
  1. Cees J. Timmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. A. Sitsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cees J. Timmer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Timmer, C.J., Sitsen, J.M.A. Single- and Multiple-Dose Pharmacokinetics and Tolerability of Gepirone Extended-Release. Clin. Drug Investig. 22, 819–826 (2002). https://doi.org/10.2165/00044011-200222120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200222120-00002

Keywords

Search

Navigation